Owen, a member of Arix Bioscience’s business development team, specialises in biotechnology. He is currently an Observer on the board of Depixus. As investment manager of ALS he has been involved with the investments in a number of companies, including Cequr, Apitope and ReNeuron. Owen also works extensively sourcing and evaluating new opportunities.
He read biology at Bristol University, qualified as an accountant at Grant Thornton and spent six years working in public and private assurance and forensic investigations.